Active substanceCholine alfoscerateCholine alfoscerate
Similar drugsTo uncover
  • Alphofolin-Lekpharm
    solution w / m in / in 
    LEKFARM, SOOO     Republic of Belarus
  • Glacer
    solution w / m in / in 
    EKOFARMPLUS, CJSC     Russia
  • Gliatilin
    solution w / m d / infusion 
    Italfarmaco SpA     Italy
  • Gliatilin
    capsulessolution inwards w / m in / in 
    Italfarmaco SpA     Italy
  • Gliatilin
    capsulessolution inwards w / m in / in 
    Italfarmaco SpA     Italy
  • Gliatilin
    solution inwards 
    Italfarmaco SpA     Italy
  • Delecite
    solution w / m d / infusion 
    ITF, LLC     Russia
  • Delecite
    capsules inwards 
    ITF, LLC     Russia
  • Noochlin Rompharm
    solution w / m in / in 
  • Choline alfoscerate
    solution w / m in / in 
    Company DEKO, LLC     Russia
  • Choline alfoscerate
    solution w / m in / in 
    PharmIntelekt, OOO     Russia
  • Choline alfoscerate
    solution w / m in / in 
  • Choline alfoscerate
    solution w / m in / in 
    ATOLL, LLC     Russia
  • Choline alfoscerate
    solution w / m d / infusion 
    BIOSINTEZ, PAO     Russia
  • Choline alfoscerate
    solution inwards 
  • Holilitil
    solution w / m in / in 
    Company DEKO, LLC     Russia
  • Holilitil
    capsules inwards 
    ARTLIFE, LLC     Russia
  • Cerepro®
    solution w / m in / in 
    VEROPHARM SA     Russia
  • Cerepro
    capsulessolution inwards w / m in / in 
    VEROPHARM SA     Russia
  • Cereton®
    solution w / m in / in 
  • Cereton
    capsules inwards 
  • Cereton®
    solution inwards 
  • Dosage form: & nbspsolution for intravenous and intramuscular administration
    Composition:
    Active substance:
    Choline alfoscerate hydrate (in terms of anhydrous substance) 250 mg
    Excipient:
    Water for injections 1 ml
    Description:
    Colorless transparent liquid.
    Pharmacotherapeutic group:Nootropic remedy
    ATX: & nbsp

    N.07.A.X.02   Choline alfoscerate

    Pharmacodynamics:
    Nootropic agent. Central cholinostimulator, which contains 40.5% of metabolically protected choline. Metabolic protection promotes the release of choline in the brain.
    Provides the synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, activates the reticular formation. Increases the linear velocity of blood flow on the side of traumatic brain injury, promotes normalization of spatiotemporal characteristics of spontaneous bioelectrical activity of the brain,regress of focal neurological symptoms and restoration of consciousness; has a positive effect on the cognitive and behavioral responses of patients with cerebral vascular diseases (discirculatory encephalopathy and residual phenomena of cerebral circulation disorders).
    Provides a preventive and corrective effect on pathogenetic factors of the involutionary psychoorganic syndrome, changes the phospholipid composition of neuronal membranes and reduces cholinergic activity.
    Stimulates the dose-dependent release of acetylcholine under physiological conditions; participating in the synthesis of phosphatidylcholine (membrane phospholipid), improves synaptic transmission, plasticity of neuronal membranes, receptor function. Does not affect the reproductive cycle, does not have a teratogenic and mutagenic effect.
    Pharmacokinetics:
    Absorption - 88%. Choline alfoscerate easily penetrates the blood-brain barrier.
    It is excreted mainly as light in the form of carbon dioxide (15%), as well as by the kidneys and through the intestine (15%).
    Indications:
    - Craniocerebral injury with predominantly stem lesion level (acute period),
    - cerebrovascular insufficiency,
    - psychoorganic syndrome on the background of degenerative diseases and involution processes of the brain,
    - multi-infarct dementia.
    Contraindications:
    - Pregnancy, breast-feeding,
    - hypersensitivity to the components of the drug,
    - age to 18 years,
    - hemorrhagic stroke (acute period).
    Dosing and Administration:
    Intramuscularly or intravenously slowly at 1000 mg / day for 15-20 days.
    When administered intravenously, the contents of one ampoule (4 ml) are diluted in physiological saline.
    Side effects:Allergic reactions, nausea.
    Overdose:Symptoms: nausea. Treatment: symptomatic.
    Interaction:Significant interaction with other drugs has not been established.
    Form release / dosage:Solution for intravenous and intramuscular injection 250 mg / ml.
    Packaging:In ampoules of neutral or light-protective glass to 4 ml. By 3 ampoules or 5 ampoules in a contour squamous package. One contour pack with instructions for medical use in a pack of cardboard.
    Storage conditions:List B. In a dry, the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:5 years.Do not use after expiry date.
    Terms of leave from pharmacies:On prescription
    Registration number:LSR-007815/09
    Date of registration:05.10.2009 / 13.08.2013
    Expiration Date:Unlimited
    The owner of the registration certificate:EKOFARMPLUS, CJSC EKOFARMPLUS, CJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp26.04.2017
    Illustrated instructions
      Instructions
      Up